Clinical Trials Logo

Clinical Trial Summary

Key words : serum, pleural effusion, procalcitonin, pneumonia Pneumonia is the common cause of pleural effusion (ranged 2nd) and bacterial infection is the main etiology of pneumonia. Procalcitonin, the prohormone of calcitonin, is a 116 amino-acid protein produced by C-cell of the thyroid gland. During severe infection, procalcitonin is probably produced by extra-thyroid tissues and the concentration increased rapidly in bacterial infection but remains low in viral infections. However, the exact origin and pathophysiological role of procalcitonin during sepsis is not clear and it is not a marker of infection as such, since localized infections or infections with no systemic manifestation cause a little if any increase in procalcitonin levels. This study will focus on assessing the value of procalcitonin in pleural effusion for diagnosis, severity and prognosis among community-acquired pneumonia with pleural effusion, such as in serum. 100 patients with clinical pneumonia infection score over six points diagnosed of community-acquired pneumonia and proved to have pleural effusion by chest sonography on admission will be studied prospectively. Serum and effusion procalcitonin levels will be measured initially and 3 days later after medical therapy. Bacterial pneumonia will be identified if bacteria was cultured from any one of the three kinds of specimen, including blood, pleural effusion or bronchoalveolar lavage. Then we will divide one hundred of patients into bacterial or non-bacterial groups. Finally, we will analyze demographic and procalcitonin data of serum and pleural effusion between these two groups and compare the difference between the severe or mild and response or non-response bacterial community-acquired pneumonia statistically.

The aim of the study will be to verify whether procalcitonin levels measured in the serum and pleural effusion could serve as a predictor for bacterial community-acquired pneumonia with pleural effusion and the different levels will also be indicative of severity and prognosis. We hope that the predictor from pleural effusion will be more sensitive or specific than that from serum and could be detectable in localized bacterial infection.


Clinical Trial Description

In this study, the first goal will be to determine the sensitivity, specificity, and predictive value of serum and pleural effusion PCT level in CAP with pleural effusion. The second goal will be to decide an appropriate value in serum or pleural effusion to assess as an index of severity and prognosis in bacterial CAP with pleural effusion. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT00646490
Study type Observational
Source Chang Gung Memorial Hospital
Contact
Status Completed
Phase N/A
Start date July 2005
Completion date July 2009

See also
  Status Clinical Trial Phase
Completed NCT02559310 - Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia Phase 3
Completed NCT01530763 - Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP) Phase 2/Phase 3
Completed NCT02517489 - Community-Acquired Pneumonia : Evaluation of Corticosteroids Phase 3
Not yet recruiting NCT01937832 - A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia Phase 3
Completed NCT02454114 - HOME FIRST Pilot: a Study of Early Supported Discharge in Patients With Lower Respiratory Tract Infections N/A
Completed NCT00653172 - Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia Phase 2
Recruiting NCT02139163 - Epidemiological Study on Community Acquired Pneumonia
Completed NCT03411824 - Lung Ultrasound for Community-acquired Pneumonia Diagnosis in Emergency Medicine
Recruiting NCT06210282 - The Effect of Focused Lung Ultrasonography on Antibiotic Prescribing in General Practice N/A
Withdrawn NCT02269644 - A P3 Comparator Trial in Community Acquired Bacterial Pneumonia Phase 3
Recruiting NCT01963442 - Short Duration Treatment of Non-severe Community Acquired Pneumonia Phase 2
Terminated NCT00887276 - Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia Phase 4
Not yet recruiting NCT00390819 - Epidemiology of Community Acquired Pneumonia in North Israel N/A
Completed NCT00079885 - Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia Phase 3
Not yet recruiting NCT04158310 - Evaluation the Clinical Value of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children
Recruiting NCT02552342 - Corticosteroid Therapy for Severe Community-Acquired Pneumonia Phase 4
Completed NCT02922387 - Smoking Cessation Intervention in Respiratory Inpatients Phase 4
Completed NCT00467701 - Community Acquired Pneumonia in Telemark and Ostfold N/A
Completed NCT04198571 - Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
Completed NCT02107001 - Lung Ultrasound in Pleuritic Chest Pain N/A